Provided by Tiger Fintech (Singapore) Pte. Ltd.

Instil Bio, Inc.

14.61
-2.0200-12.15%
Post-market: 14.610.00000.00%19:32 EDT
Volume:140.36K
Turnover:2.14M
Market Cap:95.34M
PE:-1.28
High:16.32
Open:15.02
Low:14.34
Close:16.63
Loading ...

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
18 Feb

JMP Securities Keeps Their Hold Rating on Instil Bio (TIL)

TIPRANKS
·
13 Feb

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
13 Feb

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

GlobeNewswire
·
10 Feb

3 Stocks That Could Turn $1,000 Into $5,000 by 2030

Motley Fool
·
19 Jan

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
18 Jan

Instil Bio announces clinical progress in China for IMM2510/SYN-2510

TIPRANKS
·
14 Jan

Instil Bio Inc - Plans U.S. Trial of Syn-2510/Imm2510 in 2H 2025

THOMSON REUTERS
·
14 Jan

Instil Bio Inc - Initial Clinical Data From 1L Advanced Nsclc Trial in China Expected 2H 2025

THOMSON REUTERS
·
14 Jan

Instil Bio Announces Clinical Progress in China for Imm2510/Syn-2510, a Clinical-Stage Pd-L1xvegf Bispecific Antibody

THOMSON REUTERS
·
14 Jan

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

GlobeNewswire
·
14 Jan

Jefferies Upgrades Instil Bio to Buy From Hold, Adjusts Price Target to $52 From $11

MT Newswires Live
·
07 Jan

U.S. RESEARCH ROUNDUP-CNX Resources, Inari Medical, Royal Gold

Reuters
·
07 Jan

Instil Bio Inc : Jefferies Raises to Buy From Hold

THOMSON REUTERS
·
07 Jan

Instil Bio upgraded to Buy from Hold at Jefferies

TIPRANKS
·
07 Jan

BRIEF-Instil Bio Subsidiary Secures $85.6 Million Term Loan From Midland National Life Insurance Co

Reuters
·
24 Dec 2024

Instil Bio Inc - Co's Subsidiary Secures $85.6 Mln Term Loan From Midland National Life Insurance Co

THOMSON REUTERS
·
24 Dec 2024

Instil Bio Secures Loan to Refinance Facility

TIPRANKS
·
24 Dec 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
21 Dec 2024

Thakral to enter India’s real estate sector; invests $6.37 mil in mixed-use development

Ashley Lo
·
16 Dec 2024